This segment focuses on the development, manufacturing, and distribution of rapid diagnostic tests for various infectious diseases. Research and development efforts concentrate on improving test accuracy, sensitivity, and ease of use, utilizing technologies like lateral flow assays and immunoblots. Therapeutic areas include bacteriology, virology, and parasitology, with a focus on early detection and prevention. The patient impact is significant, as rapid tests enable timely diagnosis and treatment, leading to improved patient outcomes and reduced healthcare costs. Biosynex's market positioning is strong, particularly in France and internationally, with a competitive advantage in point-of-care testing. Future opportunities include expanding the product portfolio to cover emerging infectious diseases and leveraging digital health solutions for data management and remote monitoring. Regulatory and clinical aspects involve obtaining necessary approvals and conducting clinical trials to validate test performance. Partnerships with Credo Diagnostics and PTS Diagnostics support distribution and market reach.

This segment is dedicated to developing and providing rapid diagnostic tests and related products for women's health. Research and development activities focus on creating tests for screening, diagnosis, and monitoring in areas such as pregnancy, fertility, and sexually transmitted infections. The company utilizes technologies like immunoblots and rapid test formats to provide quick and reliable results. This segment addresses critical patient needs by enabling early detection of conditions, facilitating timely interventions, and improving overall women's health outcomes. Biosynex aims to strengthen its market position by offering a comprehensive range of women's health diagnostic solutions. Future opportunities include expanding into new areas of women's health, such as oncology and genetic testing, and integrating digital health solutions for improved patient management. Regulatory compliance and clinical validation are essential aspects of this segment, ensuring the accuracy and reliability of the tests. Partnerships with healthcare providers and pharmacies are crucial for effective distribution and patient access.

This segment focuses on the development, manufacturing, and distribution of point-of-care diagnostic tests and related instruments. Research and development efforts are directed towards creating rapid, easy-to-use tests that can be performed at or near the patient, including tests for various conditions such as infectious diseases, and women's health. The company utilizes technologies like lateral flow assays and other rapid diagnostic platforms. The patient impact is significant, as POCT enables faster diagnosis, leading to quicker treatment decisions and improved patient outcomes. Biosynex aims to strengthen its market position by offering a comprehensive range of POCT solutions. Future opportunities include expanding the product portfolio to cover a wider range of diseases and conditions, and integrating digital health solutions for data management and remote monitoring. Regulatory compliance and clinical validation are essential aspects of this segment, ensuring the accuracy and reliability of the tests. Partnerships with healthcare providers, pharmacies, and distributors are crucial for effective market penetration and patient access.